Koyia Figures, MD
Geriatric Medicine · West Memphis, ARNPI 1932319449
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations.
Across 115 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$299
- Amgen$240
- Novo Nordisk$238
- Teva Pharmaceuticals USA, Inc.$223
- Sumitomo Pharma America, Inc.$201
- GSK$176
- plus $859 from 20 others
What the payments were for
- Food & beverage$2,01290%
- Education$22310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 20 | $299 |
| Amgen | 13 | $240 |
| Novo Nordisk | 14 | $238 |
| Teva Pharmaceuticals USA, Inc. | 2 | $223 |
| Sumitomo Pharma America, Inc. | 10 | $201 |
| GSK | 10 | $176 |
| Sunovion Pharmaceuticals Inc. | 8 | $147 |
| Johnson & Johnson | 5 | $80 |
| Biosense Webster, Inc. | 1 | $73 |
| Boehringer Ingelheim | 3 | $61 |
| Merck | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| AstraZeneca | 3 | $47 |
| Novartis | 3 | $47 |
| Abbott | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $43 |
| AbbVie | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $34 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Pfizer | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Smith+Nephew | 1 | $11 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,235 in reported general payments places this provider in the 85th percentile of 40 geriatric medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 456 | $205,181 |
| FarxigaDapagliflozin Propanediol | 275 | $192,428 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 129 | $115,375 |
| IngrezzaValbenazine Tosylate | 24 | $89,970 |
| JardianceEmpagliflozin | 136 | $78,860 |
| TrulicityDulaglutide | 48 | $66,277 |
| LinzessLinaclotide | 70 | $59,562 |
| MounjaroTirzepatide | 45 | $58,386 |
| GemtesaVibegron | 122 | $43,706 |
| PerserisRisperidone | 13 | $38,663 |
| OzempicSemaglutide | 24 | $33,380 |
| MyrbetriqMirabegron | 71 | $27,771 |
| JanuviaSitagliptin Phosphate | 35 | $19,588 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $17,768 |
| XareltoRivaroxaban | 40 | $15,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $47 | $205,472316 claims |
| PfizerEliquis | $18 | $205,181456 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $299 | $124,66393 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $176 | $123,557142 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $61 | $85,941150 claims |
| AbbVieLinzess, Combigan | $38 | $66,32895 claims |
| Novo NordiskOzempic, Fiasp, Levemir | $238 | $46,66979 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $201 | $43,706122 claims |
| Johnson & JohnsonXarelto, Invokana | $80 | $22,80164 claims |
| MerckJanuvia | $50 | $19,58835 claims |
| NovartisEntresto | $47 | $12,11934 claims |
| Sanofi-aventis U.S. LLCRenvela | $17 | $7,40916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 40 geriatric medicine providers in Arkansas.
Other geriatric medicine in West Memphis
- Larry JohnsonNorth Little Rock$13K
- Oumitana KajkenovaLittle Rock$5K
- Evgueni RoudachevskiLittle Rock$3K
- Gohar AzharLittle Rock$2K
- Maria Christina JuditSpringdale$1K
- Victoria AkinsLittle Rock$1K
- Raluca Rosca SichitiuJonesboro$747
- Thirumal DubbakaLittle Rock$683
- Michael YoungPrescott$681
- Maneetha KodaliLittle Rock$668
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.